new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors


Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists

Glaxo Group Limited

Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists



Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12015020917807/30/15  new patent  Liquid droplet dispenser
22015020931907/30/15  new patent  Compositions comprising an antibody and camostat mesylate (cm)
32015021076707/30/15  new patent  Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
42015021201607/30/15  new patent  Sample plate for an x-ray powder diffraction apparatus
52015020217207/23/15 Novel use
62015020385107/23/15 Inhibitors of bromodomain-containing protein pcaf for the treatment of autoimmune and inflammatory diseases or for the treatment of cancer
72015019756507/16/15 Novel ligand
82015018242707/02/15 Silica abrasive-free dentifrice composition
92015016650806/18/15 Novel compounds
102015015764006/11/15 Novel compounds
112015010817804/23/15 Re-sealable container
122015010538704/16/15 Substituted diketopiperazines and their use as oxytocin antagonists
132015009975604/09/15 Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
142015009341404/02/15 Modified antigens
152015009344004/02/15 Aggregate nanoparticulate medicament formulations, manufacture and use thereof
162015008034303/19/15 Benzofuran compounds for the treatment of hepatitis c virus infections
172015008036903/19/15 Novel compounds
182015006420103/05/15 Antigen binding proteins to oncostatin m (osm)
192015006550703/05/15 Novel compounds
202015004537502/12/15 Novel compounds
212015000410501/01/15 Novel composition
222014037848712/25/14 Tricyclic compounds, preparation methods, and their uses
232014037126412/18/14 Muscarinic acetylcholine receptor antagonists
242014033508311/13/14 Methods of treatment and prevention of eye diseases
252014031197710/23/14 Use of organic solvent nanofiltration and liquid-liquid chromatography for the recovery of pharmaceutical products
262014028813309/25/14 3 -amino- pyrazole derivatives useful against tuberculosis
272014022725908/14/14 Modified proteins and peptides
282014022726408/14/14 Drug fusions and conjugates with extended half life
292014020560407/24/14 Antigen binding constructs
302014020566107/24/14 Formulation for retinoid-containing soft gelatin capsules
312014020021807/17/14 Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
322014019340707/10/14 Drug fusions and conjugates
332014018775007/03/14 Methods for selecting protease resistant polypeptides
342014017971506/26/14 2,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
352014015870406/12/14 Medicament dispenser
362014014099605/22/14 Anti-serum albumin biding variable domains
372014011643405/01/14 Dry powder inhaler compositions
382014011292904/24/14 Tumour necrosis factor receptor 1 antagonists
392014011388804/24/14 Novel combination of therapeutic agents
402014011392204/24/14 Compounds
412014010589404/17/14 Humanized anti-il-18 antibodies
422014010591504/17/14 Bcma (cd269/tnfrsf17) - binding proteins
432014007631403/20/14 Manifold for use in medicament dispenser
442014008086303/20/14 Muscarinic acetylcholine receptor antagonists
452014005690002/27/14 Method for inhibiting binding to b-cell receptor
462014005810502/27/14 Substituted diketopiperazines and their use as oxytocin antagonists
472014005071902/20/14 Antibodies
482014005172002/20/14 N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
492014003898902/06/14 Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
502014002359601/23/14 Novel composition
512014002455801/23/14 Method of treatment
522014000517701/02/14 Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
532014000518801/02/14 Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
542013034546512/26/13 Process for the preparation of retigabine
552013033698912/19/13 Methods of identifying a patient population
562013031590111/28/13 Novel uses
572013031704111/28/13 Compounds
582013031028111/21/13 Novel antigen binding proteins
592013030233511/14/13 Ligands that bind tgf-beta receptor ii
602013026771710/10/13 Process for the preparation of atovaquone
612013026118510/03/13 Benzamide derivatives as ep4 receptor agonists
622013025172409/26/13 Antigen binding proteins to oncostatin m (osm)
632013025318809/26/13 Novel compounds
642013023750109/12/13 Benzofuran compounds for the treatment of hepatitis c virus infections
652013022420408/29/13 Method of treatment based on atad2 inhibitors
662013021315408/22/13 Method of determining cleanliness
672013021339408/22/13 Dispensing device
682013021765808/22/13 Pyrazole compounds acting against allergic, inflammatory and immune disorders
692013021089208/15/13 Method of treatment
702013020370508/08/13 Pyrazole compounds acting against allergic, immune and inflammatory conditions
712013020380208/08/13 3 -amino- pyrazole derivatives useful against tuberculosis
722013019641208/01/13 Magi polynucleotides, polypetides, and antibodies
732013018925507/25/13 Fusions and conjugates of insulinotropic agents
742013013133805/23/13 Substituted diketopiperazines as oxytocin antagonists
752013011813205/16/13 Machine and pharmaceutical and pharmaceutical-like product assembly
762013010969005/02/13 Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
772013010278304/25/13 Substituted diketopiperazines and their use as oxytocin antagonists
782013007819803/28/13 Novel use
792013005337502/28/13 Amino-quinolines as kinase inhibitors
802013003947002/14/13 Sample plate for an x-ray powder diffraction apparatus
812013004098402/14/13 7-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
822013003001201/31/13 Compounds
832013003001501/31/13 Muscarinic acetylcholine receptor antagonists
842013002354101/24/13 Voltage-gated sodium channel blockers
852013001249101/10/13 Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
862012031620212/13/12 Compounds which have activity at m1 receptor and their uses in medicine
872012030972512/06/12 Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
882012030978912/06/12 Compounds which have activity at m1 receptor and their uses in medicine
892012028854411/15/12 Novel retigabine composition
902012027727911/01/12 Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
912012025146810/04/12 Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
922012024074209/27/12 Novel device
932012024517109/27/12 Benzpyrazole derivatives as inhibitors of pi3 kinases
942012023855909/20/12 Novel compounds
952012023857109/20/12 Indazole derivatives as pi 3-kinase
962012023206109/13/12 Novel compounds
972012020774908/16/12 Dosing regimen
982012020281108/09/12 Novel compounds
992012015744606/21/12 Medical use
1002012015749106/21/12 Muscarinic acetylcholine receptor antagonists
1012012015749206/21/12 Antibiotic drug
1022012014971106/14/12 Piperidine derivatives used as orexin antagonists
1032012014973106/14/12 New medical use
1042012012868905/24/12 Anti-il-23 immunoglobulins
1052012012977805/24/12 Ligand that bind tgf-beta receptor rii
1062012011464705/10/12 Anti-serum album single variable domains
1072012010013704/26/12 Immunoglobulins
1082012010108304/26/12 S1p1 agonists comprising a bicyclic n-containing ring
1092012010108604/26/12 Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
1102012010112404/26/12 1,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
1112012010113404/26/12 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
1122012010113604/26/12 5-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
1132012006517703/15/12 Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
1142012005896303/08/12 Macrolides with anti-inflammatory activity
1152012004625802/23/12 Novel crystalline pharmaceutical product
1162012004646902/23/12 Process for the preparation of a biphenyl-2-yl carbamic acid ester
1172012003982002/16/12 Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
1182012004099102/16/12 3-azabicyclo [4.1.0] heptanes used as orexin antagonists
1192012004102702/16/12 Benzimidazoles which have activity at m1 receptor and their uses in medicine
1202012004102802/16/12 Benzimidazoles which have activity at m1 receptor and their uses in medicine
1212012003431202/09/12 4-isopropyl-3-methylphenol for the treatment of inflammation
1222012000632201/12/12 Drug dispenser
1232012000422901/05/12 Substituted diketopiperazines and their use as oxytocin antagonists
1242011031937112/29/11 Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1252011030569212/15/11 Antigen-binding contructs
1262011030569312/15/11 Anitigen-binding constructs
1272011028809811/24/11 Novel compounds
1282011028190911/17/11 Substituted quinoline derivatives as h1 receptor antagonists
1292011027565511/10/11 Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1302011027566111/10/11 Tricyclic nitrogen compounds used as antibacterials
1312011026973811/03/11 Compounds
1322011026997011/03/11 Phenethanolamine derivatives for treatment of respiratory diseases
1332011026358810/27/11 Tricyclic compounds as glutamate receptor modulators
1342011025375210/20/11 Nozzle for a nasal inhaler
1352011025607410/20/11 Novel use
1362011024547010/06/11 Immunoglobulins
1372011023779209/29/11 Quinoline derivatives and their use as 5-ht6 ligands
1382011019027408/04/11 Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1392011017806307/21/11 Benzpyrazol derivatives as inhibitors of pi3 kinases
1402011016615007/07/11 Anhydrous crystal form of ovrepitant maleate
1412011015087106/23/11 Treatment of an autoimmune disease using il-18 antagonists
1422011015226206/23/11 Novel compounds
1432011014282406/16/11 Antibodies against amyloid-beta peptide
1442011014415106/16/11 Novel process, salts, composition and use
1452011013569506/09/11 Oral dosage form for controlled drug release
1462011013042306/02/11 Compounds which have activity at m1 receptor and their uses in medicine
1472011011719005/19/11 Pharmaceutical formulations
1482011011826105/19/11 Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1492011006164603/17/11 Drug dispenser
1502011006474003/17/11 Antigen binding proteins
1512011006572503/17/11 Triazole amide derivatives for use in therapy
1522011005916703/10/11 Encapsulation of biologically active agents
1532011005997903/10/11 Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1542011004502702/24/11 Adjuvant
1552011004613702/24/11 Pyrazole derivatives as p2x7 modulators
1562011003452402/10/11 Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1572011002157801/27/11 Compounds which potentiate the ampa receptor and uses thereof in medicine
1582011000939401/13/11 Tricyclic nitrogen compounds and their use as antibacterial agents
1592011000963101/13/11 Phenethanolamine derivatives for treatment of respiratory diseases
1602010032999612/30/10 Novel combination of therapeutic agents
1612010032402212/23/10 Novel compounds
1622010031657912/16/10 Novel use of alkyl phosphate esters
1632010031766612/16/10 Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1642010031767212/16/10 Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1652010030808212/09/10 Dispensing device
1662010031170612/09/10 Method of treatment of allergic rhinitis
1672010031173412/09/10 Spiro compounds useful as antagonists of the h1 receptor
1682010030382112/02/10 Immunoglobulins
1692010030510712/02/10 Quinoline derivatives and their use as 5-ht6 ligands
1702010030512712/02/10 Novel compounds
1712010030516612/02/10 Novel compounds
1722010029222411/18/10 Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1732010029229511/18/10 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1742010028615211/11/10 N-phenyl hydrazides as modulators of the ghrelin receptor
1752010027590911/04/10 Actuator for an inhaler
1762010027385310/28/10 Novel isoindol derivatives as ep4 receptor agonists
1772010026769110/21/10 Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
1782010026773410/21/10 N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
1792010025619910/07/10 Crystalline form of an antimalarial compound
1802010025691910/07/10 Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
1812010023966609/23/10 Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
1822010022418509/09/10 Actuator for an inhaler
1832010022234909/02/10 Quinoline derivatives used to treat inflammatory and allergic diseases
1842010021679908/26/10 Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
1852010021683708/26/10 Glycine transport inhibitors
1862010021067208/19/10 Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
1872010020325608/12/10 Method and the application of powder material to substrates
1882010020424208/12/10 Piperazine derivative having affinity for the histamine h3 receptor
1892010020427308/12/10 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1902010019767908/05/10 Compounds
1912010019769908/05/10 I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
1922010019076407/29/10 Novel compounds
1932010018477007/22/10 Compounds
1942010018499607/22/10 Process of amide formation
1952010017569807/15/10 Capsule
1962010017406507/08/10 Compounds
1972010014809106/17/10 Method and system for rapid phase luminescense spectroscopy analysis
1982010015219506/17/10 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
1992010014401606/10/10 Apparatus for the disruption of animal cells
2002010014475506/10/10 Novel compounds
2012010014482906/10/10 Novel receptor antagonists and their methods of use
2022010014504006/10/10 Benzazepine derivatives for the treatment of neurological disorders
2032010013727606/03/10 Compounds which potentiate ampa receptor and uses thereof in medicine
2042010013735306/03/10 Tricyclic compounds as antibacterials
2052010013737806/03/10 Pyridine compounds for the treatment of prostaglandin mediated diseases
2062010013742806/03/10 Oxygen containing heterocycles as glycine transporter inhibiting compounds
2072010013058305/27/10 Prolinamide derivatives as modulators of voltage-gated sodium channels
2082010011352105/06/10 Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
2092010011352805/06/10 Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
2102010011379605/06/10 Indole derivatives as s1p1 receptor
2112010010565204/29/10 Purines as cysteine protease inhibitors
2122010010568804/29/10 Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
2132010010575404/29/10 5-(4phenyl)prolinamide for treatment of epilepsy
2142010008742404/08/10 Tricyclic nitrogen containing heterocycles as antibacterial agents
2152010008750204/08/10 Indazoles used to treat estrogen receptor beta mediated disorders
2162010008766704/08/10 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
2172010008183004/01/10 Methods of synthesizing n-hydroxysuccinimidyl carbonates
2182010007595303/25/10 Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
2192010007598203/25/10 Pyridinone derivative for the treatment of premature ejaculation
2202010006816603/18/10 Oral composition comprising dimethicone copolyol
2212010006940903/18/10 "novel compounds"
2222010006941603/18/10 Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2232010005905203/11/10 Sheet driver for use in a drug dispenser
2242010006309703/11/10 Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2252010005650203/04/10 Compounds
2262010005652703/04/10 Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
2272010005659503/04/10 Pyrazole derivatives as p2x7 modulators
2282010004863902/25/10 Oxadiazole derivates as s1p1 receptor agonists
2292010004167202/18/10 Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
2302010002969902/04/10 Matrix metalloproteinase inhibitors
2312010001628701/21/10 Compounds having affinity for dopamine d3 receptor and uses thereof"
2322010001637101/21/10 Indole compounds
2332010001002101/14/10 Novel compounds
2342010000052801/07/10 Manifold for use in medicament dispenser
2352010000052901/07/10 Manifold for use in medicament dispenser
2362010000342001/07/10 Medicament dispenser
2372010000423001/07/10 Azatricyclic compounds and their use
2382010000424001/07/10 Indole compounds
2392009032595212/31/09 Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2402009032603212/31/09 Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2412009031849412/24/09 Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2422009031852312/24/09 Benzoisoindole derivatives and their use as ep4 receptor agonists
2432009031853012/24/09 Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2442009031238812/17/09 Benzo [f] isoindoles as ep4 receptor agonists
2452009031254612/17/09 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2462009030605212/10/09 Indenyl derivatives and use thereof for the treatment of neurological disorders
2472009029874212/03/09 Process for manufacturing lactose
2482009029114611/26/09 Process for manufacturing lactose
2492009029198711/26/09 Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl) carbamic acid 2-(s)-hydroxymutilin 14-ester



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE